Search

Displaying results 5211 - 5220 of 9132 in total
  1. Drug

    RC118

    go.drugbank.com/drugs/DB18428
    Investigational

    RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.

  2. Drug

    Substance P

    go.drugbank.com/drugs/DB19198
    Investigational

    Substance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).

  3. Drug

    AMZ002

    go.drugbank.com/drugs/DB17017
    Investigational

    AMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.

  4. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  5. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.

  6. Drug

    Cilnidipine

    go.drugbank.com/drugs/DB09232
    Investigational

    Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.

  7. Drug

    Cefacetrile

    go.drugbank.com/drugs/DB01414
    InvestigationalVet approved

    A derivative of 7-aminocephalosporanic acid.

  8. Drug

    Prasterone sulfate

    go.drugbank.com/drugs/DB05804
    Investigational

    DHEA sulfate is the major steroid of the fetal adrenal. DHEA-S is the principal adrenal androgen and is secreted together with cortisol under the control of ACTH and prolactin. DHEA-S is elevated with hyperprolactinemia.

  9. Drug

    JTC-801 free base

    go.drugbank.com/drugs/DB17033
    Experimental

    An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]

  10. Drug

    DYN-101

    go.drugbank.com/drugs/DB17921
    Investigational

    DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.